CTEV
$16.92
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intel...
Recent News
How The Claritev (CTEV) Investment Story Is Shifting As Expectations And Valuation Reset
Claritev’s fair value price target has been reset from US$57.25 to US$44.75, a reduction of roughly 22% that marks a clear reset in expectations. Analysts are openly split on what this means, with some emphasizing Claritev’s role as a core vendor and others focusing on leverage, guidance uncertainty, and a wide range of price targets. Read on to see how these views are shaping the story around Claritev and how you can keep track as the narrative evolves. Stay updated as the Fair Value for...
Claritev Corp (CTEV) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion
Claritev Corp (CTEV) reports a 6.2% revenue increase and outlines ambitious growth plans for 2026 amidst challenges.
Claritev Q4 Earnings Call Highlights
Claritev (NYSE:CTEV) used its fourth-quarter 2025 earnings call to highlight a year of improving financial performance, an acceleration in sales activity, and continued progress on what management described as a multi-year transformation plan under its “Vision 2030” strategy. The company also issued
Claritev Corporation (CTEV) Reports Q4 Loss, Tops Revenue Estimates
Claritev Corporation (CTEV) delivered earnings and revenue surprises of -23.23% and +2.13%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
What Catalysts Are Shifting The Claritev (CTEV) Narrative Now
Claritev’s story has shifted to a more cautious footing, with the top-end fair value estimate moving from $85.00 down to $57.25 even as growth and margin assumptions remain largely intact. That reset lines up with a split analyst view, where bulls still see room above the new fair value while bears focus on leverage and a tighter range of outcomes for the broader health tech group. As this tug-of-war plays out and targets move, it is worth keeping track of how the narrative evolves so you can...